Cargando…

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Bidikian, Aram, Short, Nicholas, Ganesh, Ramya, Pike, Allison, Sasaki, Koji, Jabbour, Elias, Andreeff, Michael, Cortes, Jorge, Issa, Ghayas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429707/ http://dx.doi.org/10.1097/01.HS9.0000969652.20441.1b

Ejemplares similares

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES
por: Bidikian, Aram, et al.
Publicado: (2023)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
por: Nguyen, Daniel, et al.
Publicado: (2023)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
por: Padala, Sandeep, et al.
Publicado: (2023)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia
por: Dalle, Iman Abou, et al.
Publicado: (2020)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Configuring Windows 8: exam ref 70-687
por: Halsey, Mike, et al.
Publicado: (2013)

687. Iatrogenic Kaposi’s Sarcoma Following Treatment with Vedolizumab
por: Ajao, Susanne O, et al.
Publicado: (2020)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Exam ref 70-687: configuring Windows 8.1
por: Ballew, Joli
Publicado: (2014)

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
por: Garcia-Gutiérrez, Valentín, et al.
Publicado: (2021)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)

SUN-687 MODY-14: A Rare Cause of Inherited Diabetes
por: Epp, Riley, et al.
Publicado: (2020)

Eradication of CML stem cells
por: Carter, Bing Z., et al.
Publicado: (2016)

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
por: Hein, Kyaw, et al.
Publicado: (2022)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
por: Hijiya, Nobuko, et al.
Publicado: (2023)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
por: Hassan, Hammad, et al.
Publicado: (2023)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia
por: Tessier, Steven, et al.
Publicado: (2023)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Asciminib Mitigates DNA Damage Stress Signaling Induced by Cyclophosphamide in the Ovary
por: Mattiello, Luca, et al.
Publicado: (2021)

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES
por: Senapati, Jayastu, et al.
Publicado: (2023)

MCSA 70-687 cert guide : configuring Microsoft Windows 8.1
por: Poulton, Don, et al.
Publicado: (2015)

Charmed baryon production and decay: recent results from CLEO and E687
por: Fujino, D
Publicado: (1995)

How E687 Analized Data from the Fermilab 1990/1991 Run
por: Butler, J N
Publicado: (1992)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Corrigenda: A new species of Pristimantis from eastern Brazilian Amazonia (Anura, Craugastoridae). ZooKeys 687: 101–129 (2017). https://doi.org/10.3897/zookeys.687.13221
por: Oliveira, Elciomar Araújo De, et al.
Publicado: (2017)

ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor
por: Divisato, Giuseppina, et al.
Publicado: (2016)

687. Modeling the Impact of Introduction of Influenza Vaccination on ILI Cumulative Case Count in Cameroon
por: Tamoufe, Ubald, et al.
Publicado: (2018)

687. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Acinetobacter spp.
por: Goldberg, Joel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b9jtk172vm38t0bejkqmr47jha